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Rivaroxaban as long term therapy of recurrent 
venous thromboembolism complicated with 
repeated skin necrosis
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A 41-year-old woman with significant protein C deficiency (60%), antiphospholipid syndrome and recurrent venous throm-
boembolism (VTE), had experienced the first episode of lower limb deep vein thrombosis ten years previously. Subsequently, 
she suffered four VTE recurrences, including acute pulmonary embolism during pregnancy. She was successfully treated with 
a body weight-adjusted full dose of enoxaparin sc. In view of the potential lifelong anticoagulation, and significant subcutaneous 
haematomas at the injection sites after several years of anticoagulation with low molecular weight heparin sc, the patient was 
successfully switched to warfarin with more than a one month overlap period. She was advised to continue vitamin K antagonist 
(AVK) with a target international normalised ratio (INR) of 2.0–3.0. Approximately one year later, she was readmitted due to 
painful necrotic skin lesions of the buttock and left breast. They resolved completely after an unfractionated heparin injection 
followed by an intravenous infusion. Anticoagulation with warfarin was ceased and the patient was treated with nadroparin. 
However, she refused long term anticoagulation with subcutaneous drugs and was treated with warfarin instead, with a target INR 
of 3.0–3.5. Last year, she was admitted to our department once again because of recurrent episodes of necrotic skin lesions in 
the area over the right ilium (Fig. 1). On admission, INR was 1.8 because, by mistake, she had stopped taking warfarin two days 
earlier. We immediately ceased warfarin and administered unfractionated heparin in a bolus injection of 10,000 IU, continuing 
with an aPTT-adjusted infusion. Pending the complete regression of changes, low molecular weight heparin in a therapeutic 
dosage was recommended. After full regression of the skin lesions, we initiated treatment with rivaroxaban at 20 mg once a day. 
However, on the second day before scheduled dose of rivaroxaban we observed slight skin changes (Fig. 2), which disappeared 
spontaneously in a few hours after rivaroxaban administration. Therefore we established treatment with rivaroxaban at 15 mg 
twice a day. She was followed up for six months without any further complications, then we recommended 20 mg once a day. 
Skin necrosis during AVK treatment is a very rare complication and is usually associated with protein C deficiency, protein S deficien-
cy or antiphospholipid syndrome. Initially, the skin becomes painful, erythematous and indurated, then skin necrosis develops due 
to thrombosis of subcutaneous venules. The lesions usually occur in the fatty areas of middle-aged women who have accidentally 
omitted the drug. They require an urgent bolus of unfractionated heparin followed by UFH infusion with an aPTT-adjusted dose 
or low molecular weight heparin in 
a therapeutic dosage. The reinstitu-
tion of AVK should be started with 
very low doses with simultaneous 
heparin anticoagulation. Rivaroxa-
ban is a selective, direct factor Xa 
inhibitor. It seems to be useful in 
the chronic anticoagulant treat-
ment of patients with protein  C 
deficiency and recurrent venous 
thromboembolism, because it does 
not decrease this protein level. To 
the best of our knowledge, this is the 
first case of an effective treatment of 
a patient with protein C deficiency 
and antiphospholipid syndrome 
with rivaroxaban. 
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Figure 1. Necrotic skin lesions 
in the area over the right 
ilium in patient with signifi-
cant protein C deficiency and 
antiphospholipid syndrome
Figure 2. Slight skin changes in the same patient 
during treatment
